Valproic acid stimulates clusterin expression in human astrocytes: Implications for Alzheimer's disease

Neuroscience Letters

Volumn 475, Issue 2, 2010, Pages 64-68

  Nuutinen, Tapio ^a   Suuronen, Tiina ^a   Kauppinen, Anu ^a   Salminen, Antero ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Alzheimer's disease; Clusterin; Epigenetics; SAHA; Valproate; Vorinostat

Indexed keywords

AMYLOID BETA PROTEIN; CLUSTERIN; VALPROIC ACID; VORINOSTAT;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG POTENCY; DRUG TOLERABILITY; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GLIOMA; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ASTROCYTES; CELLS, CULTURED; CLUSTERIN; HISTONE DEACETYLASE INHIBITORS; HUMANS; VALPROIC ACID;

EID: 77952888035     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.03.041     Document Type: Article

References (48)

1. Bell R.D., Sagare A.P., Friedman A.E., Bedi G.S., Holtzman D.M., Deane R., Zlokovic B.V. Transport pathways for clearance of human Alzheimer's amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metam. 2007, 27:909-918.
2. Calero M., Rostagno A., Frangione B., Ghiso J. Clusterin and Alzheimer's disease. Subcell. Biochem. 2005, 38:273-298.
3. Carver J.A., Rekas A., Thorn D.C., Wilson M.R. Small heat-shock proteins and clusterin: intra- and extracellular molecular chaperones with a common mechanism of action and function?. IUBMB Life 2003, 55:661-668.
4. Chen J.S., Faller D.V., Spanjaard R.A. Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics?. Curr. Cancer Drug Targets 2003, 3:219-236.
5. Chuang D.M., Leng Y., Marinova Z., Kim H.J., Chiu C.T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009, 32:591-601.
6. Duenas-Gonzalez A., Candelaria M., Perez-Plascencia C., Perez-Cardenas E., de la Cruz-Hernandez E., Herrera L.A. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat. Rev. 2008, 34:206-222.
7. Faraco G., Pancani T., Formentini L., Mascagni P., Fossati G., Leoni F., Moroni F., Chiarugi A. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Pharmacol. 2006, 70:1876-1884.
8. Francis Y.I., Ma F., Ashraf H., Zhang H., Staniszevski A., Latchman D.S., Arancio O. Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J. Alzheimer's Dis. 2009, 18:131-139.
9. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., Sleeman J.P., Coco F.L., Nervi C., Pelicci P.G., Heinzel T. Valproate acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20:6969-6978.
10. Gurvich N., Tsygankova O.M., Meinkoth J.L., Klein P.S. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res. 2004, 64:1079-1086.
11. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., Jones N., Thomas C., Stretton A., Morgan A.R., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Love S., Kehoe P.G., Hardy J., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schurmann B., van den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frölich L., Hampel H., Hull M., Rujescu D., Goate A.M., Kauwe J.S., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P.P., Van Broeckhoven C., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Tsolaki M., Singleton A.B., Guerreiro R., Muhleisen T.W., Nöthen M.M., Moebus S., Jöckel K.H., Klopp N., Wichmann H.E., Carrasquillo M.M., Pankratz V.S., Younkin S.G., Holmans P.A., O'Donovan M., Owen M.J., Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41:1088-1093.
12. Jones S.E., Jomary C. Clusterin. Int. J. Biochem. Cell Biol. 2002, 34:427-431.
13. Khan O., La Thangue N.B. Drug insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat. Clin. Pract. Oncol. 2008, 5:714-726.
14. Kilgore M., Miller C.A., Fass D.M., Henning K.M., Haggarty S.J., Sweatt J.D., Rumbaugh G. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2010, (E-pub).
15. Kim H.J., Leeds P., Chuang D.M. The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J. Neurochem. 2009, 110:1226-1240.
16. Kim H.J., Rowe M., Ren M., Hong J.S., Chen P.S., Chuang D.M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 2007, 321:892-901.
17. Kostrouchova M., Kostrouch Z., Kostrouchova M. Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol. 2007, 53:37-49.
18. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., Letenneur L., Bettens K., Berr C., Pasquier F., Fievet N., Barberger-Gateau P., Engelborghs S., De Deyn P., Mateo I., Franck A., Helisalmi S., Porcellini E., Hanon O., European Alzheimer's Disease Initiative Investigators, de Pancorbo M.M., Lendon C., Dufouil C., Jaillard C., Leveillard T., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossu P., Piccardi P., Annoni G., Seripa D., Galimberti D., Hannequin D., Licastro F., Soininen H., Ritchie K., Blanche H., Dartigues J.F., Tzourio C., Gut I., Van Broeckhoven C., Alperovitch A., Lathrop M., Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41:1094-1099.
19. Leng Y., Chuang D.M. Endogenous α-synuclein is induced by Valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J. Neurosci. 2006, 26:7502-75012.
20. Leng Y., Liang M.H., Ren M., Marinova Z., Leeds P., Chuang D.M. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J. Neurosci. 2008, 28:2576-2588.
21. Loison F., Debure L., Nizard P., Le Goff P., Michel D., Le Drean Y. Up-regulation of the clusterin gene after proteotoxic stress: implication of HSF1-HSF2 heterocomplexes. Biochem. J. 2006, 395:223-231.
22. Mann L., Heldman E., Bersudsky Y., Vatner S.F., Ishikawa Y., Almog O., Belmaker R.H., Agam G. Inhibition of specific adenylyl cyclase isoforms by lithium and carbamazepine, but not valproate, may be related to their antidepressant effect. Bipolar Disord. 2009, 11:885-896.
23. Marks P.A., Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. J. Cell Biochem. 2009, 107:600-608.
24. Martel C.L., Mackic J.B., Matsubara E., Governale S., Miguel C., Miao W., McComb J.G., Frangione B., Ghiso J., Zlokovic B.V. Isoform-specific effects of apolipoprotein E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid β. J. Neurochem. 1997, 69:1995-2004.
25. May P.C., Lampert-Etchells M., Johnson S.A., Poirier J., Masters J.N., Finch C.E. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron 1990, 5:831-839.
26. Michaelis M., Doerr H.W., Cinatl J. Valproic acid as anti-cancer drug. Curr. Pharm. Des. 2007, 13:3378-3393.
27. Michel D., Chatelain G., North S., Brun G. Stress-induced transcription of the clusterin/apoJ gene. Biochem. J. 1997, 328:45-50.
28. Nuutinen T., Suuronen T., Kauppinen A., Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res. Rev. 2009, 61:89-104.
29. Nuutinen T., Suuronen T., Kyrylenko S., Huuskonen J., Salminen A. Induction of clusterin/apoJ expression by histone deacetylase inhibitors in neural cells. Neurochem. Int. 2005, 47:528-538.
30. Pasinetti G.M., Johnson S.A., Oda T., Rozovsky I., Finch C.E. Clusterin (SPG-2): a multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain. J. Comp. Neurol. 1994, 339:387-400.
31. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 2001, 276:36734-36741.
32. Prince H.M., Bishton M.J., Harrison S.J. Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res. 2009, 15:3958-3969.
33. Profenno L.A., Jakimovich L., Holt C.J., Porsteinsson A., Tariot P.N. A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease. Curr. Alzheimer Res. 2005, 2:553-558.
34. Qing H., He G., Ly P.T.T., Fox C.J., Staufenbiel M., Cai F., Zhang Z., Wei S., Sun X., Chen C.H., Zhou W., Wang K., Song W. Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioural deficits in Alzheimer's disease mouse models. J. Exp. Med. 2008, 205:2781-2789.
35. Redondo M., Tellez T., Roldan M.J. The role of clusterin (CLU) in malignant transformation and drug resistance in breast carcinomas. Adv. Cancer Res. 2009, 105:21-43.
36. Ricobaraza A., Cuadrado-Tejedor M., Perez-Mediavilla A., Frechilla D., Del Rio J., Garcia-Osta A. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 2009, 34:1721-1732.
37. Rizzi F., Bettuzzi S. The clusterin paradigm in prostate and breast carcinogenesis. Endocr. Relat. Cancer 2010, 17:R1-R17.
38. Rosemblit N., Chen C.L.C. Regulators for the rat clusterin gene: DNA methylation and cis-acting regulatory elements. J. Mol. Endocrinol. 1994, 13:69-76.
39. Rosenberg M.E., Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int. J. Biochem. Cell Biol. 1995, 27:633-645.
40. Saura J., Petegnief V., Wu X., Liang Y., Paul S.M. Microglial apolipoprotein E and astroglial apolipoprotein J expression in vitro: opposite effects of lipopolysaccharide. J. Neurochem. 2003, 85:1455-1467.
41. Schroeder F.A., Lin C.L., Crusio W.E., Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol. Psychiatry 2007, 62:55-64.
42. Stephen L.J. Drug treatment of epilepsy in elderly people. Focus on valproic acid. Drugs Aging 2003, 20:141-152.
43. Tariot P.N., Raman R., Jakimovich L., Schneider L., Porsteinsson A., Thomas R., Mintzer J., Brenner R., Schafer K., Thal L. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. Am. J. Geriatr. Psychiatry 2005, 13:942-949.
44. Waldecker M., Kautenburger T., Daumann H., Busch C., Schrenk D. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J. Nutr. Biochem. 2008, 19:587-593.
45. Wilson M.R., Easterbrook-Smith S.B. Clusterin is a secreted mammalian chaperone. Trends Biochem. Sci. 2000, 25:95-98.
46. Zhang X.Z., Li X.J., Zhang H.Y. Valproic acid as a promising agent to combat Alzheimer's disease. Brain Res. Bull. 2010, 81:3-6.
47. Zlokovic B.V., Martel C.L., Matsubara E., McComb J.G., Zheng G., McCluskey R.T., Frangione B., Ghiso J. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:4229-4234.
48. Zlokovic B.V., Yamada S., Holtzman D., Ghiso J., Frangione B. Clearance of amyloid β-peptide from brain: transport or metabolism?. Nat. Med. 2000, 6:718-719.